|

Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVD

RECRUITINGSponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Actively Recruiting
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Started2024-07-09
Est. completion2029-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06637657

Summary

The goal of this observational study is to evaluate the implementation of a 'first-time-right' pharmacological treatment strategy in patients hospitalized with coronary artery disease. The main question it aims to answer is: Does early (immediately post-event) initiation of a full set of guideline-based, individualized, preventive medication lead to reductions in cardiovascular events compared to current practice (incremental titration strategies)? Researchers will compare the 'first-time-right' strategy group to the current practice group to see if there are improvements in major adverse cardiac and cerebrovascular events (MACE) at 36 months. Participants will: * Receive either the 'first-time-right' strategy or current practice for secondary prevention. * Be monitored (data collection) through routine clinical visits at baseline, 8 weeks, 12, and additional telephone contacts at 24, and 36 months after discharge. * Complete online questionnaires at hospitalization, 8 weeks, 12, 24, and 36 months after discharge.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* \>18 years of age (no upper limit)
* Coronary event, i.e. ACS or coronary revascularisation
* Able to provide informed consent

Exclusion Criteria:

* (short-term planned) pregnancy or breast feeding
* Dialysis

Conditions2

Acute Coronary SyndromeHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.